MIL-OSI UK: expert reaction to study on workplace exposure to metals and pesticides and cardiovascular disease

Source: United Kingdom – Executive Government & Departments

Research published in Heart suggests that working with metals and pesticides could be risk factors for cardiovascular disease specifically among Hispanic/Latino workers.


Dr Wayne Carter, Associate Professor, University of Nottingham, said:

“This paper is an interesting insight into potential risk factors for cardiovascular disease (CVD) associated with chronic occupational exposures.  However, one must be cautionary to extrapolate these findings because of study limitations that include no direct measurements (for example via urinary metabolites) of metal or pesticide exposures, the reliance on self-reported/perceived exposures, the use of catchall terms (metals and pesticides) without agent-specific assessments, and a lack of quantification of domestic exposures.

“Therefore chronic exposure to metals and pesticides may be a risk factor for CVD but further evidence is required to support a causal relationship and one that is both agent (which particular metal or pesticide) and dose-response specific.”


‘Association of occupational exposures with cardiovascular disease among US Hispanics/Latinos’ by Catherine Bulka et al. was published in Heart at 23:30 UK time on Tuesday 11th December.

Declared interests

 Dr Wayne Carter: ‘No conflicts of interest’


MIL-OSI UK: expert reaction to study looking at statins dose/adherence and cardiovascular deaths

Source: United Kingdom – Science Media Centre

Research published in JAMA Network Open demonstrates that lowest cardiovascular risk was seen among patients with high intensity statin treatment and good adherence.

Prof Liam Smeeth, Professor of Clinical Epidemiology and GP, London School of Hygiene and Tropical Medicine, said:

“This is a well done study showing that the greatest benefits from statins are obtained by people who take their statins on most days or everyday, and among people on higher doses of statins. These results are entirely in agreement with the evidence from previous clinical trials, showing that statins prevents heart attacks and deaths due to cardiovascular disease. The study highlights the importance of people taking their statins reliably over the long term, and the benefits of using the higher doses of statins that are now widely recommended in clinical guidelines.”

Prof Sir Nilesh Samani, Medical Director at the British Heart Foundations, said:

“This is real-world evidence that taking your medicine as prescribed really can make all the difference.  If you’re taking statins, it’s essential that you continue to take them regularly, as advised by your doctor.  This is even more important if you’re at high risk, which includes people who’ve already had a heart attack or stroke, or those who have inherited high cholesterol levels.

“This isn’t the first study to show how important adherence is, but it’s a timely reminder given the misinformation about statins that may stop some people from taking them as prescribed.”

‘Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe’ by Kamlesh Khunti et al. was published in JAMA Network Open at 16:00 UK time on Friday 7 December 2018.

Declared interests

Prof Liam Smeeth: “Professor Smeeth reports grants from Wellcome, grants from MRC, grants from NIHR, grants from GSK, grants from BHF, grants from Diabetes UK, none of which are directly relevant to this paper.  He is the principal investigator of the Statinwise trial, funded by NIHR, to investigate adverse effects of statins.  He is a Trustee of the British Heart Foundation.”

None others received.